South San Francisco, United States
NewLimit is a promising player in the Biotechnology and Health Care industries, aiming to revolutionize human healthspan through cutting-edge epigenetic reprogramming therapies. Founded in 2022 and headquartered in the United States, the company focuses on treating age-related diseases by rejuvenating the epigenome, thereby restoring the regenerative capabilities of aged and diseased cells.
The startup employs advanced techniques like functional genomics, pooled perturbation screening, and machine learning models to explore the biology of aging on an unprecedented scale. These innovative methods position NewLimit as a front-runner in combating age-related health decline.
In a significant Series C round on June 1, 2026, NewLimit secured $435.00M in funding from a prestigious group of investors including Founders Fund, Kleiner Perkins, and Lilly Ventures. This substantial backing underscores investor confidence and supports the company's ambitious goals to extend human healthspan.
